<prompt> Tetrabenazine acts by inhibitingMAO-BVesicular monoamine transpoerDopamine D2 receptorsCOMT  <response>: Tetrabenazine: Inhibit VMAT 2vesicular monoamine transpoer, which transpo dopamine and norepinephrine into adrenergic vesicle in nerve ending. Use for treatment of chorea in Huntington and tardive dyskinesia. In above figure: Pharmacologic strategies for dopaminergic therapy of Parkinsons disease. Drugs and their effects are indicated see text. MAO, monoamine oxidase; COMT, catechol-O-methyltransferase; DOPAC, dihydroxyphenylacetic acid; L-DOPA, levodopa; 3-OMD, 3-O-methydopa; 3-MT, 3-methoxytramine. 